Evaluation of the efficiency and safety of combined therapy with a symptomatic sustained-release drug and hyaluronic acid versus monotherapy with hyaluronic acid in patients with knee osteoarthritis

Osteoarthritis (OA) is the most common joint disease. Searching for new treatment methods and regimens for OA is relevant.

Objective: to evaluate the efficiency and safety of therapy with a symptomatic sustained-release drug (Alflutop) in combination with intra-articular hyaluronic acid (HA) injection versus monotherapy with HA in patients with knee OA in routine clinical practice.

Patients and methods. A post-registration open-labeled prospective comparative randomized study was conducted to assess the results of treatment in 76 patients (31 men and 45 women; mean age, 49.3±8.5 years; body mass index, 28.4±0.8 kg/m2 ) in two clinical centers in Yekaterinburg and Perm. The patients were randomized into two equal groups, were homogeneous in terms of gender, the frequency of comorbidities, and vital signs (blood pressure, heart rate, and respiratory rate).
Group 1 patients received Alflutop as 1-ml daily intramuscular injections (a total of 20 injections) + 2 ml of 1% intraarticular (IA) HA solution injections three times at 1-week intervals; Group 2 patients were given 2 ml of 1% intraarticular HA solution injections three times at 1-week intervals. As an additional therapy, the use of meloxicam 7.5–15 mg/day was permitted, and, if non-steroidal anti-inflammatory drugs were contraindicated, paracetamol 1–3 g/day might be used.

Results and discussion. During treatment, both groups of patients showed improvement (compared to the baseline levels). At the same time, evaluating the intergroup values revealed clear differences: a more pronounced decrease in all WOMAC indicators in Group 1 patients: pain scores, 2 [1; 3] vs. 4 [2; 5] in Group 2 (p<0.001); stiffness, 1 [0; 2] vs. 2 [1; 4] (p<0.001); functional insufficiency, 8 [3; 12] vs. 15.5 [12; 20] (p<0.001); and total WOMAC scores, 12 [7; 13] vs. 21.5 [15; 28] (p<0.001). Pain-intensity assessment using the visual analogue scale also showed the more pronounced positive effect of the combination therapy in Group 1 (p<0.001).
Alflutop used in combination with HA was shown to be more preferable than HA monotherapy, which was confirmed by the results achieved for all WOMAC indicators. At 6 months, by the last visit, there were pronounced positive changes in all the analyzed parameters in both groups. At the same time, the most significant changes were recorded in the Alflutop + HA group than in the HA group (p<0.001). Perhaps, the mechanism in exhibiting the found synergistic effect of these drugs lies in their different effect on the pathogenesis of the disease. However, further study of this issue is required in multicenter randomized controlled trials.
The good safety of the drugs was confirmed: not a single adverse event was revealed.

Conclusion. The patients receiving the combination therapy with Alflutop + HA had the best treatment results in all the parameters assessed.

1. Martynov AI, Naumov AV, Vertkin AL, et al. Management of patients with osteoarthritis and comorbidity in General medical practice: expert opinion based on evidence-based medicine. Lechashchii vrach. 2015;(4):39-46. (In Russ.).

2. Cleveland RJ, Nelson AE, Callahan LF. Knee and hip osteoarthritis as predictors of premature death: a review of the evidence. Clin Exp Rheumatol. 2019 Sep-Oct;37 Suppl 120(5):24-30. Epub 2019 Oct 14

3. Wilkie R, Parmar SS, Blagojevic-Bucknall M, et al. Reasons why osteoarthritis predicts mortality: path analysis within a cox proportional hazards model. RMD Open 2019; 5:e001048. doi:10.1136/rmdopen-2019-00104.

4. Hawker GA . Osteoarthritis is a serious disease. Clin Exp Rheumatol. Sep-Oct 2019;37 Suppl 120(5):3-6.

5. Alekseeva LI, Taskina EA, Kashevarova NG, et al. Knee osteoarthritis and metabolic syndrome: new approaches to therapy. Nauchnoprakticheskaya revmatologiya = Rheumatology Science and Practice. 2018;56(2):157-63. (In Russ.). doi: 10.14412/1995-4484-2018157-163

6. Bruyere O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019 Dec; 49(3):337-350. doi: 10.1016/j.semarthrit.2019.04.008. Epub 2019 Apr 30.

7. Ministry of health of the Russian Federation. Osteoarthrosis. Clinical recommendations. Moscow; 2016.

8. Alekseeva LI, Sharapova EP, Taskina EA, et al. Multicenter double-blind randomized placebo-controlled trial of the symptom- and structure-modifying effect of alflutop in patients with knee osteoarthrosis. Communication 1. Evaluation of the symptom-modifying effect of the drug. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51(5):532–8. (In Russ.). doi: 10.14412/1995-4484-2013-1545.

9. Alekseeva LI, Sharapova EP, Taskina EA, et al. A multicenter, blind, randomized, placebo-controlled study of the symptomand structure-modifying effet of alflutop in patients with knee osteoarthritis. Report 2: the assessment of the structure-modifying effect of the drug. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(2):174–7. (In Russ.). doi: 10.14412/1995-4484-2014-174-177

10. Levin OS, Olyunin DYu, Golubeva LV. Alflutop efficacy in chronic vertebrogenous lumbar ischialgia. A double blind placebo controlled study. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2004;42(4):80-4. (In Russ.). doi: 10.14412/1995-4484-2004-809.

11. Olariu L, Dimitriu B, Buse E, Rosoiu N. The invitro effect of Alflutop product on some extracellular signaling factors involved in the osteoarticular pathology inflammation. Academy of Romanian Scientists. Annals Series on Biological Sciences. 2015;4(2):7-17.

12. Olariu L, Pyatigorskaya N, Dimitriu B, et al. «In vitro» chondro-restitutive capacity of Alflutop proved on chondrocytes cultures. Roman Biotech Letters. 2016; 22(6):12047-53.

13. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, аnd years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1789-1858. doi: 10.1016/S0140-6736(18)32279-7

14. Altman RD, Manjoo A, Fierlinger A, et al. The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review. BMC Musculoskelet Disord. 2015 Oct 26;16:321. doi: 10.1186/s12891-015-0775-z

15. Tosun HB, Gü rger M, Gü mü stas SA, et al. The effect of sodium hyaluronate-chondroitin sulfate combined solution on cartilage formation in osteochondral defects of the rabbit knee: an experimental study. Ther Clin Risk Manag. 2017 Apr 18;13:523-532. doi: 10.2147/TCRM.S133635

16. Altman RD, Akermark C, Beaulieu AD, et al. Efficacy and safety of a single intraarticular injection of non-animal stabilized hyaluronic acid (NASHA) in patients with osteoarthritis of the knee. Osteoarthritis Cartilage. 2004 Aug;12(8):642-9. doi: 10.1016/j.joca.2004.04.010.

17. Kellgren JH, Jeffrey M, Ball J. Atlas of standard radiographs.Vol. 2. Oxford: Blackwell Scientific; 1963.

18. Altman R, Hackel J, Niazi F, et al. Efficacy and safety of repeated courses of hyaluronic acid injections for knee osteoarthritis: A systematic review. Semin Arthritis Rheum 2018 Oct;48(2):168-175. doi: 10.1016/j.semarthrit.2018.01.009. Epub 2018 Jan 31.

19. Miller L, Fredericson M, Altman R. Hyaluronic Acid Injections or Oral Nonsteroidal Anti-inflammatory Drugs for Knee Osteoarthritis: Systematic Review and Meta-analysis of Randomized Trials. Orthop J Sports Med. 2020 Jan 27;8(1):232596711 9897909. doi: 10.1177/2325967119897909.

20. Alekseeva LI, Taskina EA, Lila AM, et al. A multicenter, prospective, randomized trial of the efficacy and safety of Alflutop® in an alternating dosing regimen versus the standard one. Communication 1: Evaluation of the efficacy of the drug in different treatment regimens. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2019;13(3): 51-9. (In Russ.). doi: 10.14412/1996-70122019-3-51-59

21. Sharapova EP, Alekseeva LI, Taskina EA, et al. A multicenter, prospective, randomized trial of the efficacy and safety of Alflutop ® in an alternating dosing regimen versus the standard one. Communication 2: Evaluation of the efficacy of the drug in different use regimens. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2020;15(1):67–73. (In Russ.). doi: 10.14412/1996-7012-20201-67-73

22. Maheu E, Zaim M, Appelboom T, et al. Evaluation of intra articular injections of hyaluronic acid and chondroitine sulfate for knee arthritis treatment: a multicentric pilot study with 3 monts follow-up. National rheumatolgy meeting 2010 (Societe Francaise de Rhumatologie).

23. Henrotin Y, Hauzeur JP, Bruel P, Appelboom T. Intra-articular use of a medical device composed of hyaluronic acid and chondroitin sulfate (Structovial CS): effects on clinical, ultrasonographic and biological parameters. BMC Res Notes. 2012 Aug 4; 5:407. doi: 10.1186/1756-0500-5-407.

24. Rivera F, Bertignone L, Grandi G, et al. Effectiveness of intra-articular injections of sodium hyaluronate-chondroitin sulfate in knee osteoarthritis: a multicenter prospective study. J Orthop Traumatol. 2016 Mar;17(1): 27-33. doi: 10.1007/s10195-015-0388-1. Epub 2015 Nov 14.